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 Isoniazid, rifampicin and pyrazinamide are 
essential first-line anituberculosis (anti-TB) drugs1 
which have hepatotoxic potential. Drug induced 
hepatotoxicity (DIH) is a commonly encountered 
Role of acute viral hepatitis as a confounding factor in 
antituberculosis treatment induced hepatotoxicity 
Pawan Sarda, S.K. Sharma, Alladi Mohan*, Govind Makharia**, Arvind Jayaswal+, R.M. Pandey++ & 
Sarman Singh#
The Division of Pulmonary, Critical Care & Sleep Medicine, Department of Medicine, All India Institute of 
Medical Sciences, New Delhi, *Division of Pulmonary & Critical Care Medicine, Department of Medicine
Sri Venkateswara Institute of Medical Sciences, Tirupati, +Departments of Gastroenterology & Human 
Nutrition Unit, +Orthopaedics, ++Biostatistics & #Laboratory Medicine, All India Institute of Medical 
Sciences, New Delhi, India
Received February 14, 2008
Background & objectives: Drug induced hepatotoxicity (DIH) is an important and commonly encountered 
adverse effect with antituberculosis (anti-TB) treatment. Acute viral hepatitis (AVH) is an important 
confounding reason which clinically, biochemically and histologically mimics DIH.
Methods: The  contributory role of acute viral hepatitis as a confounding factor in patients with normal 
baseline liver functions who developed acute hepatitis while receiving short-course anti-TB treatment 
was prospectively studied. The sera of all patients who developed acute hepatitis were analysed for 
markers for hepatitis A, B, C and E viruses.
Results: Viral hepatitis was present in 15  of the 102 (14.7%) patients who developed acute hepatitis while 
receiving anti-TB treatment with hepatitis E virus being the most common cause Later onset of  acute 
hepatitis [58 (5-133) vs. 26 (3-221) days; P=0.04], large elevations in aspartate aminotransferase (AST) [371 
(30-2643) vs. 212 (63-1990 IU/l); P=0.03] and alanine aminotransferase (ALT)  [388 (31-2997) vs. 225 (52-
1670 IU/l); P= 0.002]  and a longer time for normalization of deranged liver functions [36.7 ± 13.3 vs. 24.5 ± 
19.3 days; P=0.02] indicated acute viral hepatitis as the cause of liver function derangement.
Interpretation & conclusions: Our findings showed AVH in 14.7 per cent patients who developed 
hepatotoxicity while an anti-TB treatment. Therefore, in endemic areas, viral hepatitis should be sought 
after and excluded in all patients suspected to have DIH before attributing the hepatotoxic effect to the 
anti-TB drugs.
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adverse effect with anti-TB treatment that frequently 
results in interruption of treatment2-4. 
 The incidence of acute hepatitis in patients 
receiving short-course anti-TB treatment has varied 
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widely and may depend on grade of trasnaminase 
elevation1. However, what is perceived as anti-TB 
DIH may not be drug-induced all the time. Acute 
viral hepatitis is an important confounding illness 
which clinically, biochemically and histologically 
mimics DIH5. As not much is known, we prospectively 
studied contributory role of acute viral hepatitis as a 
confounding factor in patients with anti-TB DIH.
Material & Methods
 During the period January 2005 to December 
2006, 2906 patients were treated for various forms 
of tuberculosis (TB) disease at the Medicine out-
patient department, Chest Clinic, and medical wards 
of All India Institute of Medical Sciences (AIIMS), 
New Delhi and Sri Venkateswara Institute of Medical 
Sciences (SVIMS), Tirupati. In all of the patients 
baseline liver functions were within normal limits 
before starting anti-TB treatment. Of these, 102 
(3.5%) patients [74 of 2128 (3.5%) from New Delhi; 
28 of the 778 (3.6%), from Tirupati] who developed 
acute hepatitis while receiving short-course anti-TB 
treatment3 were prospectively studied. Patients who 
were human immunodeficiency virus (HIV) positive, 
patients with chronic liver disease, chronic alcoholics 
(consumption of 48 g ethanol per day for more than 
a year) and those receiving other hepatotoxic drugs 
concomitantly, were excluded from the study. All 
patients gave informed written consent and Ethics 
Committees of both institutes approved the study. 
 The serum samples of all patients who developed 
acute hepatitis were analysed for viral hepatitis markers3 
and antibodies to HIV6 as described previously. During 
treatment, liver enzymes and bilirubin were measured 
once in two weeks for initial two months and thereafter 
monthly and whenever the patients presented with 
clinical features of acute hepatitis. Abdominal 
ultrasonography was done in all patients to rule out 
other causes of liver disease. Biochemical testing was 
carried out in serum samples using Beckman Synchron 
Cx9 Clinical System Autoanalyser and system packs 
(Beckman-Coulter Inc, Fulterton, CA, USA). The same 
protocol and methods of estimation were followed at 
both the centres.
 Acute hepatitis was defined as described previously3 
by the presence of at least one of the following criteria: 
(i) a rise of five times the upper limit of normal levels 
(50 IU/l) of serum aspartate aminotransferase (AST) 
and/or alanine aminotransferase (ALT); (ii) a rise in 
the level of serum total bilirubin (>1.5 mg/dl); (iii) 
any increase in AST and/or ALT above pre-treatment 
levels together with anorexia, nausea, vomiting, and 
jaundice. 
 After detection of DIH or acute viral hepatitis, the 
potentially hepatotoxic drugs isoniazid, rifampicin 
and pyrazinamide were immediately stopped. These 
patients were followed up every week until the clinical 
and biochemical parameters of hepatic injury became 
normal. During this period anti-TB drugs devoid of 
hepatotoxic potential such as ethambutol, streptomycin, 
and a fluoroquinolone (ofloxacin, levofloxacin) were 
administered. Once the liver functions normalized, the 
first-line anti-TB drugs were re-introduced.
Statistical analysis: The demographic parameters, type 
of TB, time for development of hepatotoxicity,  various 
laboratory parameters and time for normalization of the 
liver function tests between patients who developed 
DIH and those who had acute viral hepatitis were 
compared using Fisher’s exact test, Student’s t-test and 
Mann-Whitney U test. Statistical software package 
SPSS (version 10.0, SPSS Inc, Chicago, IL, USA) was 
used for analysis.
Results
 The mean age of the patients who developed 
acute hepatitis (n=102) was 34.7±12.7 yr; there were 
47 males; 24 (23.3%) had pulmonary TB, 52 (50.5%) 
had extrapulmonary TB and 26 (25.2%) patients had 
disseminated/miliary TB. Majority of the patients 
(n=92; 90%) presented with symptoms of acute 
hepatitis such as anorexia, nausea, vomiting; clinically 
evident jaundice was present in 30 (29.4%) patients. 
Only 10 (9.8%) of 102 patients had asymptomatic 
elevation of liver enzymes.  
 Fifteen (14.7%) patients had serological evidence 
of acute viral hepatitis. Serological evidence confirmed 
recently acquired acute viral hepatitis A in 1 (6.7%), 
hepatitis B in 2 (13.3%), hepatitis C in 3 (20%) and 
hepatitis E in 8 (53.3%) patients; hepatitis E was the 
most common cause of viral hepatitis (Table I). 
 In patients with acute viral hepatitis, the onset 
of acute hepatitis was delayed compared with those 
with DIH (P=0.04). The extent of elevation of AST 
(P=0.03) and ALT (P=0.002) was significantly higher 
in patients with acute viral hepatitis compared to 
those who had DIH (Table II). Furthermore, time 
taken for normalization of liver functions was 
significantly longer in patients with acute viral hepatitis 
compared to those with DIH (P=0.02). The abdominal 
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ultrasonography findings were similar in patients with 
acute viral hepatitis and DIH.
Discussion
 Wide variations have been reported in the incidence 
of hepatotoxic reactions during anti-TB treatment1. The 
figures are much higher in studies from developing 
countries compared to those from developed countries 
despite using similar regimens3. Perhaps poor nutrition, 
increased age, widespread parasitism, chronic 
infections, alcoholism, indiscriminate use of drugs 
without prescription, ethnic factors, severity of disease 
or genetic predisposition may play a role individually 
or collectively1-3.  
 Kumar et al5 from India highlighted another 
reason for this disparity. They reported that 17 of the 
40 children (42.5%) who had acute hepatitis while on 
anti-TB drugs, had serological evidence of acute viral 
hepatitis A or B. Turktas et al7 reported viral hepatitis B 
and C in 10 of the 57 (17.5%) patients who developed 
acute hepatitis while receiving anti-TB therapy. 
Serological tests for non-A, non-B5 and hepatitis E7 
viruses were not performed in these studies. In the 
present study, we found that 14.7 per cent patients 
with acute hepatitis had acute viral hepatitis; hepatitis 
E being the most common cause. Given that India is 
hyperendemic for hepatitis E virus8, this observation 
is not surprising. Our data suggest that, in endemic 
areas, if appropriate serological testing is not done, 
patients who develop acute viral hepatitis while on 
anti-TB treatment may be misdiagnosed and labelled 
as DIH instead. Our observations also suggest that 
later onset of acute hepatitis, large elevations in hepatic 
transaminases and a longer time for normalization 
indicate acute viral hepatitis rather than DIH and these 
factors may guide the clinicians to suspect and look for 
viral hepatitis. 
 Recognising acute viral hepatitis in patients with 
sputum smear-positive pulmonary TB being treated 
for TB is important because, the longer duration for 
normalization (during which time a less efficient 
modified treatment regimen incorporating non-
hepatotoxic drugs is being used), will also facilitate 
disease transmission and development of drug 
resistance especially in patients with a high bacillary 
load. In India9, and other developing countries, 
baseline liver function testing and  serological testing 
to exclude viral hepatitis are not routinely performed 
under National TB Control Programmes where 
majority of the patients get treated. The problem may 
Table I. Positive serological markers for viral hepatitis in patients 
(n=15) who developed acute hepatitis while receiving anti-TB 
treatment
Positive viral marker No. (%)
Anti-HAV IgM antibody 1 (6.7)
HBsAg, Anti-HBc IgM antibody 2 (13.3)
Anti-HCV  IgM antibody 3 (20)
Anti-HEV IgM antibody 8 (53.3)
Anti-HCV and  Anti-HEV IgM antibody 1 (6.7)
HAV, hepatitis A virus; HBsAg, hepatitis B surface antigen; 
HBcAg, hepatitis B core antigen; HCV, hepatitis C virus; HEV, 
hepatitis E virus; IgM, immunoglobulin M 
Table II. Comparison between patients who developed drug 
induced hepatotoxicity (DIH) and those who had viral hepatitis
Variables DIH
(n=87)
Viral hepatitis
(n=15)
P value
Age (yr) 34.97 ± 12.53 32.87 ± 13.66 0.56
Sex: Male
        Female
40 (46%)
47 (54%)
7 (47%)
8 (53%) 0.96
Type of TB: 
Pulmonary
Extra-pulmonary
Disseminated/miliary
21 (24%)
44 (51%)
22 (25%)
3 (20%)
8 (53%)
4 (27%) 0.94
BMI (kg/m2)* 18.8 ± 2.6 19.6  ± 2.6 0.28
MAC (cm)* 22.1 ± 3.1 23.2 ± 2.7 0.21
Total serum proteins 
(g/dl)*
7.45 ± 0.65 7.88 ± 0.78 0.06
Baseline serum albumin 
(g/dl)*
3.8 ± 0.7 4.1 ± 0.7 0.15
Baseline serum bilirubin 
(mg/dl)*
0.6 ± 0.1 0.7 ± 0.1 0.85
Baseline serum AST 
(IU/l)*
35.8 ± 9.7 36.7 ± 10.0 0.70
Baseline serum ALT 
(IU/l)*
36.3 ± 11.5 32.2 ± 11.3 0.21
Base line serum ALP 
(IU/l)
160.0 ± 60.69 125.2 ± 43.9 0.06
Latent period (days)† 26 (3-221) 58 (5-133) 0.04
Maximum serum  
bilirubin  (mg/dl)†
1.8 (0.5-9.7) 3.1 (0.5-14.1) 0.13
Maximum serum 
AST(IU/l)†
212 (63-1990) 371 (30-2643) 0.03
Maximum serum ALT 
(IU/l)†
225 (52-1670) 388 (31-2997) 0.002
Maximum serum ALP 
(IU/l)†
180 (38-883) 165 (77-1631) 0.44
Time taken for 
normalization of the liver 
function tests (days)
24.5 ± 19.30 36.7 ± 13.3 0.02
*Expressed as mean ± standard deviation; †expressed as 
median with range; BMI, body mass index; DIH, drug induced 
hepatotoxicity; MAC, mid-arm circumference; AST, aspartate 
aminotransferase; ALT, alanine aminotransferase; ALP, alkaline 
phosphatase
66 INDIAN J MED RES, JANUARY 2009
become more profound in patients with HIV-TB co-
infection who get treated with antiretroviral drugs with 
hepatotoxic potential in addition to anti-TB drugs10. 
 Consensus guidelines for the management of TB in 
patients with deranged liver functions either due to DIH 
or due to acute viral hepatitis are yet to be evolved1. 
Once there is evidence of acute hepatitis, it is essential 
to first stop all potentially hepatotoxic drugs such as 
isoniaizd, rifampicin, and pyrazinamide till complete 
clinical and biochemical resolution of hepatotoxicity 
occurs. In the interim period, at least three non-
hepatotoxic drugs viz., ethambutol, streptomycin 
and quinolones such as ofloxacin can be used after 
appropriate checks on renal function and visual acuity. 
After complete resolution of transaminitis, most anti-
tuberculosis drugs can be safely restarted in a phased 
manner.
 National TB Control Programmes in resource-
limited nations should provide guidelines and also 
make provision for the treatment of TB in settings of 
DIH and acute viral hepatitis. These guidelines could 
include provision of alternative, non hepatotoxic drugs 
and/or treatment interruption followed by a carefully 
monitored, systematic re-introduction of the first-line 
drugs with hepatotoxic potential. 
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